Article Information
PubMed
Print ISSN
Online ISSN
History
- Received November 1, 2006
- Accepted March 2, 2007
- Published online May 18, 2007.
Article Versions
- Earlier version (March 7, 2007 - 08:06).
- You are viewing the most recent version of this article.
Copyright & Usage
The American Society for Pharmacology and Experimental Therapeutics
Author Information
- Amit S. Kalgutkar,
- Deepak K. Dalvie,
- Jiri Aubrecht,
- Evan B. Smith,
- Stephanie L. Coffing,
- Jennifer R. Cheung,
- Chandra Vage,
- Mary E. Lame,
- Phoebe Chiang,
- Kim F. McClure,
- Tristan S. Maurer,
- Richard V. Coelho, Jr.,
- Victor F. Soliman and
- Klaas Schildknegt
- Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research and Development, Groton, Connecticut (A.S.K., C.V., M.E.L., T.S.M., V.F.S.) and La Jolla, California (D.K.D., E.B.S.); and Safety Sciences (J.A., S.L.C., J.R.C.), Cardiovascular and Metabolic Diseases Chemistry (P.C., K.F.M.), and Chemical Research and Development (K.S., R.V.C.), Pfizer Global Research and Development, Groton, Connecticut
- Address correspondence to:
Dr. Amit S. Kalgutkar, Pharmacokinetics, Dynamics, and Metabolism Department, Pfizer Global Research and Development, Groton, CT 06340. E-mail: amit.kalgutkar{at}pfizer.com
Statistics from Altmetric.com
Article usage
In this issue
Genotoxicity of 2-(3-Chlorobenzyloxy)-6-(piperazinyl)pyrazine, a Novel 5-Hydroxytryptamine2c Receptor Agonist for the Treatment of Obesity: Role of Metabolic Activation
